Mechanistic Insights into the Racemization of Fused Cyclopropyl Isoxazolines.


Journal

Organic letters
ISSN: 1523-7052
Titre abrégé: Org Lett
Pays: United States
ID NLM: 100890393

Informations de publication

Date de publication:
20 03 2020
Historique:
pubmed: 21 12 2019
medline: 21 12 2019
entrez: 21 12 2019
Statut: ppublish

Résumé

Experimental and computational studies of the unexpected racemization of enantiopure fused cyclopropyl isoxazolines are reported. These studies offer insights into the mechanism of racemization, quantify the position of the transition state on the dipolar-diradical continuum, and establish a relationship between the structure and stability of this class of compounds. Experimental and computed energy barriers for racemization are also presented.

Identifiants

pubmed: 31859518
doi: 10.1021/acs.orglett.9b04236
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2113-2117

Auteurs

Kyle W Quasdorf (KW)

Departments of Chemical Process Research and Development and Therapeutic Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States.

Adam B Birkholz (AB)

Departments of Chemical Process Research and Development and Therapeutic Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States.

Michael D Bartberger (MD)

1200 Pharma LLC, 844 East Green Street, Suite 204, Pasadena, California 91101, United States.

John Colyer (J)

Departments of Chemical Process Research and Development and Therapeutic Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States.

Stephen Osgood (S)

Departments of Chemical Process Research and Development and Therapeutic Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States.

Kevin Crossley (K)

Departments of Chemical Process Research and Development and Therapeutic Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States.

Seb Caille (S)

Departments of Chemical Process Research and Development and Therapeutic Discovery, Amgen, Inc., One Amgen Center Drive, Thousand Oaks, California 91320, United States.

Classifications MeSH